Ice cold to success! Ultra-low temperature specialist Lowenco reports record year in turnover and earnings

Founded in 2013, our portfolio company Lowenco is already one of the leading providers of ultra-low temperature solutions for the global biopharma industry after just a few years. A success that is also reflected in the company’s books. As of 31.12.2021, Lowenco reports an increase in operating profit of around 32 percent to now 80 million Danish Kroner. For the future, Lowenco sees further growth potential and sets the highest quality standards and an extremely customer-oriented service for the growing biopharma industry. With the support of SHS as an experienced industry investor, Lowenco will continue its expansion.

More information: https://t1p.de/cvy7o